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Abstract
Introduction: Epirubicin is a common adjuvant treatment for breast cancer. It is mainly eliminated after
glucuronidation through uridine diphosphate-glucuronosyltransferase 2B7 (UGT2B7). The present study aimed to
describe the impact of the UGT2B7
His268Tyr polymorphism on invasive disease-free survival in breast cancer patients
after epirubicin treatment.
Methods: This is a pharmacogenetic study based on samples collected from 745 breast cancer patients of the
Austrian Tumor of breast tissue: Incidence, Genetics, and Environmental Risk factors (TIGER) cohort who did not
present metastases at baseline. This cohort included 205 women with epirubicin-based combination
chemotherapy, 113 patients having received chemotherapy without epirubicin and 427 patients having received
no chemotherapy at all. Of the epirubicin-treated subgroup, 120 were subsequently treated with tamoxifen. For all
women UGT2B7
His268Tyr was genotyped. Invasive disease-free survival was assessed using Kaplan-Meier and Cox’s
proportional hazard regression analysis.
Results: Among the 205 epirubicin-treated patients, carriers of two UGT2B7
268Tyr alleles had a mean invasive
disease-free survival of 8.6 (95% confidence interval (CI) 7.9 to 9.3) years as compared to 7.5 (95% CI 6.9 to 8.0)
years in carriers of at least one UGT2B7
268His allele (adjusted hazard ratio (HR) = 2.64 (95% CI 1.22 to 5.71); P =
0.014). In addition, the impact of the UGT2B7
His268Tyr polymorphism became even more pronounced in patients
subsequently treated with tamoxifen (adjusted HR = 5.22 (95% CI 1.67 to 26.04); P = 0.015) whereas no such
difference in invasive disease-free survival was observed in patients not receiving epirubicin.
Conclusions: Breast cancer patients carrying the UGT2B7
268Tyr/Tyr genotype may benefit most from adjuvant
epirubicin-based chemotherapy. These results warrant confirmation in further studies.
Introduction
Anthracyclines are commonly used for neoadjuvant or
adjuvant chemotherapy of locally advanced breast cancer
[1,2]. They act by inhibition of topoisomerase II alpha
and generation of reactive oxygen species eventually
resulting in cell cycle arrest and apoptosis [3,4]. Epirubi-
cin is a semisynthetic derivative of doxorubicin preferen-
tially used in breast cancer treatment. It is extensively
metabolized in the liver to epirubicinol by aldo-keto
reductase and in addition aglycones of epirubicin and
epirubicinol are formed [5]. The major inactivation
pathway for epirubicin and epirubicinol is glucuronida-
tion catalysed by UDP-glucuronosyltransferases (UGT).
Studies using human liver microsomes, expressing
UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9,
UGT2B7 and UGT2B15 revealed that UGT2B7 uniquely
converts epirubicin to its glucuronide [6]. In addition,
also the active metabolites of tamoxifen are eliminated
by UGT2B7 mediated glucuronidation [7].
The UGT2B7 gene is polymorphic with a frequent
non-synonymous variant 802 C > T leading to a histi-
dine to tyrosine substitution in codon 268 (His268Tyr).
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as studies have shown lower [8-12], similar [13-15], and
even higher enzyme activity of the UGT2B7
268Tyr iso-
form [16-18]. Two in vitro studies showed no impact of
the UGT2B7
His268Tyr genotype on the epirubicin glucur-
onide formation [6,19]. However, the presently available
in vitro studies cannot finally clarify, if variants linked
with the UGT2B7
His268Tyr polymorphism may modulate
up- or downregulation of the enzyme under the condi-
tions of adjuvant or neoadjuvant chemotherapy and in
vitro models can, of course, never fully resemble the in
vivo conditions [19-22]. UGT2B7 haplotype analysis
revealed six promoter variants (-1306 G > A, -1299C >
T, -1112C > T, -900A > G, -327G > A and -161C > T)
which modulate UGT2B7 promoter activity and are in
perfect linkage disequilibrium with the UGT2B7
His268Tyr
variant [19,20,22,23]. In contrast, for 4-hydroxy-tamoxi-
fen and endoxifen, the active metabolites of tamoxifen, a
decreased glucuronidation activity was shown for the
UGT2B7
268Tyr isoform in vitro [9].
Here we present a pharmacogenetic (PGt) analysis of
the Austrian Tumor of breast tissue: Incidence, Genet-
ics, and Environmental Risk factors (TIGER)s t u d y
[24,25] to explore the effect of the UGT2B7
His268Tyr
polymorphism on invasive disease-free survival after
epirubicin treatment.
Materials and methods
Study design
T h eT I G E Rs t u d yw a sac o h o r ts t u d yt oi n v e s t i g a t e
genetic and environmental risk factors relevant to the
onset and course of breast cancer [24,25]. As described
earlier [26], the complete cohort consisted of 804 con-
secutive women with histologically confirmed breast
cancer and no other cancer diagnosis, treated at the
Division of Oncology, Department of Internal Medi-
cine, Medical University Graz, Austria between January
2000 and September 2004. For the purpose of this PGt
study, patients presenting with metastases already at
baseline (stage IV) or not having biomaterial available
for PGt analyses were excluded. At stage IV host
genetic polymorphisms were considered much less
relevant for survival and sample size in this subgroup
was too small (n = 38) to allow adjustment or stratified
analysis for this stage of disease. Patients were regu-
larly followed-up with clinical examinations, laboratory
(including CEA and CA15-3), radiological (bone scan,
liver scan, chest X-ray, and mammograms), and gyne-
cological analyses at three-year intervals until 2010
[24].
The study complied with the Declaration of Helsinki
and was performed according to the Austrian Gene
Technology Act. The protocol has been approved by the
Ethical Committee of the Medical University Graz.
Written informed consent was obtained from all partici-
pating subjects.
UGT2B7 genotyping
DNA was isolated from venous blood (Qiamp DNA
Mini-Kit, Qiagen, Hilden, Germany). Genotyping for
UGT2B7 802 C > T was performed blinded to the clini-
cal outcomes using the validated TaqMan
® SNP Geno-
typing Assay (C__32449742_20, Applied Biosystems,
Foster City, CA, USA). Real-time PCR reactions were
set up in a final volume of 12.5 μlc o n t a i n i n gT a q M a n
®
Genotyping Master Mix, 20 × SNP Genotyping Assay
(Applied Biosystems, Foster City, CA, USA) distilled
water and 3 to 20 ng genomic DNA. PCR amplification
was carried out using the Real Time PCR System 7300
(Applied Biosystems) under the following conditions: 10
minutes 95°C enzyme activation followed by 40 cycles at
92°C for 15 s and at 60°C for 1 minute.
Statistical analysis
Invasive disease-free survival was defined as the time
from diagnosis to any local, regional, or distant recur-
rence, metastases or contralateral breast cancer or death
from any cause, but excluded second primary invasive
cancer to consider only events which may reflect effi-
cacy of initial epirubicin drug treatment [27]. Kaplan-
Meier estimates were calculated and the log-rank test
was used to compare invasive disease-free survival of
different UGT2B7
His268Tyr variant carriers after (1) adju-
vant chemotherapy with epirubicin, (2) adjuvant che-
motherapy with epirubicin and tamoxifen, (3) adjuvant
chemotherapy other than epirubicin, or (4) no adjuvant
chemotherapy at all. In the latter two subgroups no dif-
ference was expected and thus served as controls. Cox’s
proportional hazard modeling was used for subsequent
multivariate analyses with adjustments for clinical prog-
nostic factors such as tumor size, age at diagnosis, nodal
status, and histological grade. Proportional hazards were
assessed by Schoenfeld residuals as well as by including
the interaction terms of covariates with time into the
model. Possible differences in patient characteristics
between the respective treatment and genotype groups
were assessed using Chi-square test, Kruskal-Wallis test
or Mann-Whitney test. All tests were two-sided, per-
formed at a significance level of 0.05 using SPSS 17.0
(SPSS Inc., Sunnyvale, CA, USA).
Results
Study population
Of the original 804 patients of the TIGER cohort, 59
patients were excluded from this analysis due to
metastases already at baseline, the lack of material for
PGt analyses, or the revision of the breast cancer diag-
nosis during follow-up (Figure 1). Of the remaining
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tion chemotherapy, 113 combination chemotherapy
without epirubicin (mostly cyclophosphamide, metho-
trexate and fluorouracil), and 427 no adjuvant che-
motherapy at all. Of the 205 epirubicin-treated
patients, 120 subsequently also received tamoxifen
(Figure 1).
Invasive disease-free survival by treatment
Patients who underwent adjuvant chemotherapy signifi-
cantly differed from the remaining patients in clinical
prognostic factors such as age, tumor size, grade, and
nodal status (Table 1). Mean invasive disease-free survi-
val times differed accordingly, with 7.9 years (95% confi-
dence interval (CI) 7.4 to 8.3) in epirubicin-treated
patients, 6.9 years (95% CI 6.1 to 7.6) in patients with
adjuvant therapy other than epirubicin, and 9.1 years
(95% CI 8.8 to 9.4) in the remaining patients. Corre-
sponding rates of patients with disease progression dur-
ing a mean follow-up period of 6.6 ± 2.0 years were
27.8%, 46.9%, and 18.3%, respectively.
Invasive disease-free survival by UGT2B7
His268Tyr
genotype
In the entire cohort, 147 (19.7%) patients carried two
histidine alleles, 352 (47.2%) were heterozygous and 246
(33.0%) carried two tyrosine-alleles. UGT2B7
268Tyr allele
frequency was 57% and genotype frequencies matched
Hardy Weinberg equilibrium (Chi square test, P = 0.27).
Neither did frequencies of genotypes vary significantly
among the three different treatment groups (Chi-square,
P = 0.93) nor did epirubicin-treated carriers of different
variants differ in tumor size, grade, and nodal status at
baseline (Table 2). However, carriers of at least one
UGT2B7
268His allele were slightly older than non-car-
riers at baseline (54.4 ± 10.2 versus 50.1 ± 10.7; Mann-
Whitney test, P = 0.01).
In epirubicin-treated patients an association between
the UGT2B7
His268Tyr polymorphism and invasive dis-
ease-free survival was observed (log-rank P = 0.05). By
comparing carriers and non-carriers of the UGT2B7
268-
His allele a significantly increased relapse risk was
observed for the carriers of the UGT2B7
268His allele
Figure 1 Patient flow chart based on the original TIGER cohort. AI, aromatase inhibitor, TIGER, Austrian tumor of breast tissue: incidence,
genetics, and environmental risk factors study.
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relapses and other events constituting a disease progres-
sion were 33.1% and 15.2% in carriers and non-carriers
of the UGT2B7
268His allele, respectively. Accordingly,
carriers of at least one UGT2B7
268His allele had a shorter
mean invasive disease-free survival time of 7.5 years
(95% CI 6.9 to 8.0) as compared to 8.6 years (95% CI
7.9 to 9.3) in UGT2B7
268Tyr/Tyr carriers (Figure 2a, Table
3). The unadjusted hazard ratio (HR) for carriers of at
least one UGT2B7
268His allele was 2.24 (95% CI 1.13 to
4.44; P =0 . 0 2 1 ) .C o x ’s regression models with adjust-
ment for age at diagnosis, nodal status and tumor grade,
stratified by tumor size due to non proportional hazard,
resulted in an only slightly deviating adjusted HR of
2.64 (95% CI 1.22 to 5.71; P = 0.014).
Interestingly, in the subgroup of patients subsequently
treated with tamoxifen the effect of the UGT2B7
268His
allele to indicate a poor prognosis became even more
pronounced (Figure 2b, Table 3) with an adjusted HR of
5.22 (95% CI 1.67 to 26.04; P = 0.015). However, in this
model the Firth correction was applied as all patients
with nodal status 0 were censored [28].
In the patient subgroup not receiving epirubicin, but
tamoxifen in monotherapy (n = 305), there was no asso-
ciation of invasive disease-free survival with the
UGT2B7
His268Tyr genotype (log-rank P = 0.20), as well as
in any other patient group not receiving epirubicin (Fig-
ure 3, Table 3).
Discussion
Genetic polymorphisms that might be relevant to drug
metabolism and elimination have extensively been stu-
died over the last years to explain between-subject varia-
tion in drug responses and to better target
corresponding treatments [29-32]. Particularly in breast
cancer, genetic polymorphisms of proteins involved in
drug transport or metabolism have been shown to affect
the efficacy of agents such as tamoxifen, taxanes or aro-
matase inhibitors [7,33,34]. A considerable variation in
the response to epirubicin-based chemotherapies has
been reported as well [35-37].
The formation of epirubicin glucuronide represent the
main inactivating pathway for epirubicin and studies in
human liver microsomes expressing a multitude of UGT
isoenzymes, revealed that UGT2B7 uniquely converts
Table 1 Baseline characteristics by treatment
Adjuvant chemotherapy Epirubicin No epirubicin None P*
Total patients No. (%) 205 (27.5%) 113 (15.2%) 427 (57.3%)
Age in years (mean, SD) 53.0 (10.5) 55.6 (12.6) 60.5 (12.0) < 0.001
Tumor size < 0.001
≤ T1 (≤ 20 mm) 75 (36.6%) 59 (52.2%) 296 (69.3%)
≥ T2 127 (62.0%) 50 (44.2%) 121 (28.3%)
unknown 3 (1.5%) 4 (3.5%) 10 (2.3%)
Lymph nodes < 0.001
0 32 (15.6%) 45 (39.8%) 262 (61.4%)
≥ 1 162 (79.0%) 57 (50.4%) 131 (30.7%)
unknown 11 (5.4%) 11 (9.7%) 34 (8.0%)
Grade < 0.001
1 3 (1.5%) 4 (3.5%) 45 (10.5%)
2 63 (30.7%) 31 (27.4%) 260 (60.9%)
> 2 128 (62.4%) 77 (68.1%) 107 (25.1%)
Unknown 11 (5.4%) 1 (0.9%) 15 (3.5%)
* P-values are indicated for the comparison of patients treated with adjuvant chemotherapy (with or without epirubicin) vs. patients not treated with any
adjuvant chemotherapy.
SD, standard deviation
Table 2 Characteristics of epirubicin-treated patients by
UGT2B7
His268Tyrgenotype
UGT2B7
268 Genotype Tyr/Tyr His/Tyr + His/His P
Number (%) 66 (32.2%) 139 (67.8%)
Age in years (mean, SD) 50.1 (10.7) 54.4 (10.2) 0.01
Tumor size 0.12
≤ T1 (≤ 20 mm) 29 (43.9%) 46 (33.1%)
≥ T2 35 (53.0%) 92 (66.2%)
unknown 2 (3.0%) 1 (0.7%)
Lymph nodes 0.73
0 12 (18.2%) 20 (14.4%)
≥ 1 50 (75.8%) 112 (80.6%)
unknown 4 (6.1%) 7 (5.0%)
Grade 0.62
1 1 (1.5%) 2 (1.4%)
2 17 (25.8%) 46 (33.1%)
> 2 43 (65.2%) 85 (61.2%)
Unknown 5 (7.6%) 6 (4.3%)
SD, standard deviation
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knowledge, this is the first study providing evidence that
genetic UGT2B7 variation contributes to these clinical
observations. In our analysis, epirubicin-treated women
with the UGT2B7
268Tyr/Tyr genotype showed a
significantly better invasive disease-free survival as com-
pared to carriers of at least one UGT2B7
268His allele. As
the use of epirubicin is quite common and the differ-
ence in the average invasive disease-free survival times
between both variant carriers amounted to about one
year, we think this finding might be of broad interest
and high relevance in cancer therapy, although it still
needs to be confirmed.
A lower glucuronidation capacity of the UGT2B7
268Tyr
isoform may delay elimination and cause higher expo-
sure to epirubicin and its active metabolites. This may
eventually result in the observed longer invasive disease-
free survival of carriers of the UGT2B7
268Tyr/Tyr geno-
type. This is in line with biochemical studies revealing a
decreased activity of the UGT2B7
268Tyr isoforms asses-
sing other UGT2B7 substrates [8-12]. However, those
were contradicted by others [13-18] and by two in vitro
studies showing no impact of the UGT2B7
His268Tyr geno-
type on the epirubicin glucuronide formation [6,19].
Figure 3 Kaplan-Meier plots of invasive disease-free survival
depending on the UGT2B7
His268Tyr genotype in control patients.
(a) Patients receiving a combination chemotherapy not containing
epirubicin or (b) no adjuvant chemotherapy at all.
Figure 2 Kaplan-Meier plots of invasive disease-free survival
depending on the UGT2B7
His268Tyr genotype in epirubicin-
treated patients. (b) epirubicin-treated patients subsequently
treated with tamoxifen.
Table 3 Invasive disease-free survival according to
UGT2B7
His268Tyr genotype and treatment
Hazard ratio (95% CI)
Adjuvant chemotherapy Crude Adjusted
Epirubicin 2.24 (1.13 to 4.44) 2.64 (1.22 to 5.71)
P = 0.021 P = 0.014
Epirubicin/tamoxifen 4.43 (1.34 to 14.6) 5.22 (1.67-26.04)
P = 0.015 P = 0.015)
No epirubicin 0.80 (0.43 to 1.49) 0.78 (0.40 to 1.50)
P = 0.48 P = 0.45
None 0.80 (0.47 to 1.34) 0.87 (0.49 to 1.55)
P = 0.39 P = 0.64
CI, confidence interval.
Parmar et al. Breast Cancer Research 2011, 13:R57
http://breast-cancer-research.com/content/13/3/R57
Page 5 of 8One of these studies utilized two lines of HK293 cells
expressing the two isoforms generated via site-directed
mutagenesis [6]. This methodology implies the disad-
vantage that the variant leading to an amino acid
exchange is solely studied, whereas potentially linked
variants remain unconsidered [6,16]. This seems to be
important, since the UGT2B7
His268Tyr variant appears in
frequent haplotypes with other variants, especially pro-
moter variants (-1306 G > A, -1299C > T, -1112 C > T,
-900 A > G, -327 G > A and -161 C > T) which seem
to influence the expression of the two UGT2B7
His268Tyr
isoforms [13,19-22]. The variant alleles of those promo-
ter variants were associated with a two-fold decreased
promoter activity and are perfectly linked with the
UGT2B7
268Tyr allele [22]. Djebli et al. genotyped the
-900 A > G promoter variant beside UGT2B7
His268Tyr
and they reported that all individuals carrying the
-900GG genotype carried also two variant UGT2B7
268Tyr
alleles and those who were heterozygote for the promo-
ter variant were as well heterozygote for UGT2B7
His268-
Tyr [21]. Using the tagging algorithm implemented in
Haploview and the genotype frequencies for the Hap-
Map CEU samples we observed that UGT2B7
His268Tyr
a n dt h el i n k e dp r o m o t e rv a r i a n t sc a p t u r e d8 3 %o fa l l
genotyped markers (applying a r
2 cut-off of 0.8, minor
allele frequency > 0.05, and using NM_001074 +/- 10
kb) [38,39]. The UGT2B7
His268Tyr variant is further
linked to the rather rare promoter variant -138 G > A
(less than 2% in Caucasians) which was associated with
a seven-fold decreased promoter activity and it cannot
be excluded if this variant contributes to our observa-
tions [22]. The presently available in vitro studies cannot
finally clarify, if those promoter variants may modulate
up- or downregulation of the enzyme, especially under
the conditions of adjuvant or neoadjuvant chemother-
apy. Therefore, it remains unclear if our observations
can be mainly attributed to the UGT2B7
His268Tyr variant
or to the expressional regulation caused by linked pro-
moter variants. However, in human liver microsomes,
genotyped for UGT2B7
His268Tyr, no difference related to
this polymorphism in epirubicin glucuronide formation
was observed [19], but it is conceivable that there is an
up- or downregulation of UGT2B7 caused by anti-can-
cer drug therapy which may differ inter-individually
depending on genetic variants. Whether or not this does
play a relevant role in epirubicin treatment cannot
finally be clarified by our study but may be an interest-
ing topic for further research. Sawyer et al.a l s o
observed differences in morphine glucuronidation study-
ing the linked UGT2B7 -161 C > T variant in pain
patients, but failed to confirm their finding in genotyped
microsomes [18]. This may indicate differences between
the in vitro and the in vivo impact of the variant or the
associated UGT2B7 haplotypes.
A few studies have investigated the impact of the
UGT2B7
268Tyr variant on the in vivo metabolism of
other drugs. For mycophenolic acid (MPA), a lower glu-
curonidation activity and MPA-acyl-glucuronide forma-
tion rate through the UGT2B7
268Tyr variant was shown
[21,40], which resulted in fewer gastrointestinal side-
effects among MPA treated patients [41]. However, in
contrast to MPA-acyl-glucuronide [41,42], the glucuro-
nide of epirubicin are not known to contribute consider-
ably to the side effects of the parental drug. Moreover,
changes in drug tolerability may affect efficacy outcomes
only if those result in changes in treatment adherence.
Actually, we have neither data on epirubicin dose modi-
fications and premature discontinuations nor on the
incidence of adverse drug reactions. Additionally, an
association of the linked UGT2B7 -161 C > T variant
with pharmacokinetics of lamotrigine in epileptic
patients has been recently reported [43]. By contrast, no
effect was observed either on pharmacokinetics of efa-
virenz or zidovudine in human immunodeficiency virus
infected patients [44,45], or on the treatment response
to various opioids [46-48]. Given that our study was a
retrospective analysis, we unfortunately were not able to
determine plasma levels of drug compounds or metabo-
lites. A possible influencing factor might be the younger
age among UGT2B7
268Tyr/Tyr carriers in the epirubicin
treated patients group, but although age is a relevant
covariate for survival, the relatively small difference in
mean age between the different UGT2B7 genotypes is
v e r yu n l i k e l yt oe x p l a i nam a j o rp a r to ft h er e l a t i v e l y
strong UGT2B7 effects on survival after epirubicin treat-
ment. In addition, we observed no difference in patient
age comparing the UGT2B7 genotype groups within the
other patient subgroups and no association between age
at diagnosis and outcome in the multivariate analysis.
Besides, a link to breast cancer risk has also been dis-
cussed for the UGT2B7
His268Tyr polymorphism, but no
clear evidence has been reported and it is very unlikely
that this is a contributing factor to our observations
[49,50].
In addition, the association of the UGT2B7
268Tyr var-
iant with invasive disease-free survival was even more
pronounced in the subgroup of epirubicin-treated
women who subsequently received tamoxifen (Figure
2b). Actually, in vitro data suggested reduced glucuroni-
dation rates of the active metabolites 4-hydroxy tamoxi-
fen and endoxifen through the UGT2B7
268Tyr isoform
[9], but in contrast to epirubicin, sulfotransferases also
play a quantitatively important role [51]. Accordingly,
no difference in steady state plasma concentrations of
tamoxifen metabolites was observed in 240 breast cancer
patients receiving 20 mg tamoxifen daily [52]. In the
present study, the sequential treatment with two
UGT2B7 substrates resulted in a considerable effect of
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His268Tyr variant, whereas there was no dif-
ference in invasive disease-free survival among patients
not treated with epirubicin, including the subgroup of
women treated with tamoxifen alone. The more pro-
nounced effect of the UGT2B7
His268Tyr polymorphism in
patients treated with both epirubicin and tamoxifen
remains currently unexplained and is limited by the
rather small sample size of this patient subgroup.
Conclusions
Breast cancer patients carrying the UGT2B7
268Tyr/Tyr
genotype may benefit most from adjuvant epirubicin-
based chemotherapy. Prospective studies with pharma-
cokinetic measurements and fixed treatment regimens
are warranted.
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